<?xml version="1.0" encoding="UTF-8"?>
<p id="para1800">The prevalence of detectable HCV RNA in the general population in 2014 was approximately 0·9% (range 0·7–1·0%), of Australia representing 227 000 people (range 167 620–249 710).
 <xref rid="bib75" ref-type="bibr">
  <sup>75</sup>
 </xref> However, the number of new HCV infections in Australia has declined since 2000, with modelling studies suggesting that incidence peaked at 14 000 infections in 1999 and then fell to 8500–9000 in 2013 in young adults (aged 20–39 years).
 <xref rid="bib80" ref-type="bibr">80</xref>, 
 <xref rid="bib81" ref-type="bibr">81</xref> This decline is attributed to the improvement in harm reduction measures and a reduction in the prevalence of the use of injectable drugs.
 <xref rid="bib82" ref-type="bibr">
  <sup>82</sup>
 </xref> 8% of newly diagnosed cases of HCV in 2014 were in Aboriginal people.
 <xref rid="bib83" ref-type="bibr">
  <sup>83</sup>
 </xref> The notification of newly diagnosed HCV cases in Aboriginal people increased by 38%, from 119 per 100 000 people in 2010 to 164 per 100 000 in 2014.
 <xref rid="bib83" ref-type="bibr">
  <sup>83</sup>
 </xref> By contrast in non-Aboriginal people, notification of new cases decreased by 15%, from 41 per 100 000 people in 2010 to 35 per 100 000 in 2014.
 <xref rid="bib83" ref-type="bibr">
  <sup>83</sup>
 </xref>
</p>
